Sweden · Delayed Price · Currency is SEK Elekta AB Earnings Call Transcripts
Fiscal Year 2026
-
Management outlined a turnaround strategy focused on innovation, operational excellence, and regional growth, targeting mid-single digit revenue CAGR and 14%-16% EBIT margin by 2028/2029. Key levers include adaptive radiotherapy, software/service expansion, and disciplined commercial execution, with strong positions in Europe, the U.S., and China.
-
Transformation and cost-saving initiatives drove improved profitability, with EBITDA margin at a seven-year high and net debt reduced. Stricter order criteria and a SEK 1.4 billion impairment improved earnings quality, while outlook remains positive with further margin gains expected.
-
Solid Q3 performance with improved margins and strong order growth in China and the U.S., despite FX and tariff headwinds. Restructuring is nearly complete, with over SEK 500 million in annual savings expected from Q1 next year.
-
Four strategic priorities are driving transformation: operational simplification, focused innovation, regional growth in China and the US, and ongoing cost reduction. Decentralization, new leadership, and a shift to faster, customer-driven innovation cycles are underway, with significant savings and market share gains expected.
-
Q2 saw modest organic growth, margin improvement, and strong cash flow, with Europe leading performance and China showing order recovery. A new operating model and 10% workforce reduction target SEK 500 million in cost savings, while order backlog was cleaned up with no revenue impact.
-
Q1 saw 3% sales growth in constant currency, led by strong EMEA performance and new product launches, but margins declined due to FX and tariffs. U.S. and China remain weak, with recovery in China expected in H2, and full-year sales growth guidance is reiterated.
Fiscal Year 2025
-
Profitability and margin expansion are prioritized through product mix, price increases, and operational rigor. Strong market positions in Europe and China, software growth, and asset-light upgrades drive recurring revenue. Order backlog quality and SaaS adoption are improving predictability and customer value.
-
Book-to-bill remained strong, with net sales up 1% for the year and 6% in Q4, driven by new product launches and robust software growth. Adjusted gross margin reached a five-year high in Q4, while a SEK 1.64 billion non-cash impairment impacted net income. Outlook anticipates sales and margin expansion despite FX headwinds.
-
Net sales grew 2% year-over-year, with strong order growth and margin improvement driven by new product launches and service expansion. Guidance was revised downward due to lower US and China volumes, but long-term EBIT margin targets remain intact.
-
Net sales declined 4% year-over-year, with gross margin and EBIT margin under pressure from lower sales, market mix, and FX. Strong order growth in China and new product launches are expected to drive improved sales and profitability in the second half, with mid-single digit growth and EBIT margin expansion targeted for the full year.
-
Net sales grew 1% in constant currencies, with strong U.S. installations and a major order in Mexico. Margins remain under pressure from inflation, but sequential improvement and cost-saving initiatives are underway. Full-year sales are expected to grow mid-single digits, with margin expansion in H2.
Fiscal Year 2024
-
Rising cancer rates and staff shortages are driving demand for productivity-enhancing radiotherapy innovations. Recent launches like Elekta Evo and Elekta ONE Planning, featuring AI-enhanced imaging and adaptive workflows, are seeing strong adoption and price uplifts. Upgrade opportunities and a comprehensive, interoperable portfolio are expected to boost margins and recurring revenues.
-
Net sales grew 5% year-over-year, with strong cash flow and margin expansion, but Q4 saw a 2% sales decline due to lower installations in mature markets and inflationary pressures. The outlook anticipates a weaker first half of FY 2024-2025, with recovery expected in the second half from new product launches and productivity measures.